A Wall Street analyst has provided a review for the Healthcare company today, but retained the same rating on the stock. Analyst Justin Keywood from Stifel Nicolaus reiterated a Buy rating on Medexus Pharmaceuticals Inc (MDP – Research Report), with a C$3.50 price target.
According to TipRanks.com, Keywood is a 1-star analyst with an average return of -0.9% and a 38.2% success rate. Keywood covers the Healthcare sector, focusing on stocks such as Andlauer Healthcare Group, Cipher Pharmaceuticals, and Knight Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Medexus Pharmaceuticals Inc with a C$3.64 average price target, which is an 82.0% upside from current levels. In a report released yesterday, Canaccord Genuity also upgraded the stock to Buy with a C$3.75 price target.
Medexus Pharmaceuticals Inc’s market cap is currently C$40.83M and has a P/E ratio of 8.99.
Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.
The company’s shares closed last Friday at C$1.92.
